eliglustat   Click here for help

GtoPdb Ligand ID: 7536

Synonyms: GENZ-112638
Approved drug
eliglustat is an approved drug (FDA (2014), EMA (2015))
Compound class: Synthetic organic
Comment: The marketed formulation contains eliglustat tartrate (PubChem CID 52918379).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 12
Topological polar surface area 71.03
Molecular weight 404.27
XLogP 3.66
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCCCCCC(=O)NC(C(c1ccc2c(c1)OCCO2)O)CN1CCCC1
Isomeric SMILES CCCCCCCC(=O)N[C@@H]([C@@H](c1ccc2c(c1)OCCO2)O)CN1CCCC1
InChI InChI=1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)/t19-,23-/m1/s1
InChI Key FJZZPCZKBUKGGU-AUSIDOKSSA-N
References
1. Larsen SD, Wilson MW, Abe A, Shu L, George CH, Kirchhoff P, Showalter HD, Xiang J, Keep RF, Shayman JA. (2012)
Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain.
J Lipid Res, 53 (2): 282-91. [PMID:22058426]
2. Lukina E, Watman N, Arreguin EA, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Kamath RS, Rosenthal DI et al.. (2010)
Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study.
Blood, 116 (20): 4095-8. [PMID:20713962]
3. Lukina E, Watman N, Dragosky M, Pastores GM, Arreguin EA, Rosenbaum H, Zimran A, Angell J, Ross L, Puga AC et al.. (2014)
Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.
Blood Cells Mol Dis, 53 (4): 274-6. [PMID:24835462]